{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-027165","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2026-08-12T13:30:54+00:00","discovered_at":"2026-08-12T13:32:00.273135+00:00","generated_at":"2026-08-12T13:32:25.629070+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Monopar Q2 net loss $5.3M; initiates rolling NDA for ALXN1840","bullets":["Net loss $5.3M ($0.62/share) vs $2.5M ($0.35) in Q2 2025; R&D spend $4.77M (up from $1.73M).","Cash and investments $134.3M as of June 30, 2026; runway through at least Dec 31, 2027.","Rolling NDA submission to FDA for ALXN1840 initiated July 22, 2026; RPD designation granted June 30, 2026.","RPD designation supports potential pediatric Priority Review Voucher at NDA approval; commercial team added.","Positive Phase 3 FoCus data presented at EAN 2026 and AAN 2026 showing neurologic benefit vs standard of care."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-027165","json":"https://secwatch.observer/filing/0001437749-26-027165.json","markdown":"https://secwatch.observer/filing/0001437749-26-027165.md","text":"https://secwatch.observer/filing/0001437749-26-027165.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000143774926027165/0001437749-26-027165-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000143774926027165/mnpr20260811_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T13:32:25.629070+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}